注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Kiora Pharmaceuticals Inc(原名:Eyegate Pharmaceuticals Inc)是一家臨床階段的製藥公司。該公司致力於開發和商業化治療炎症和免疫疾病的產品,重點是眼部和神經系統產品。該公司的產品線包括KIO-101、KIO-301和KIO-201,用於常見和罕見眼病的早期到後期開發。 KIO-101是一種非甾體、免疫調節和小分子二氫乳清酸脫氫酶 (DHODH) 抑製劑。該公司的KIO-301是一種光敏小分子,用作可逆光開關,旨在恢復視力受損患者的眼睛感知和解釋光線的能力。該公司的KIO-201是一種天然聚合物透明質酸,旨在保護眼表以允許角膜上皮再生並改善眼表完整性。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Daniel S. Durrie | 73 | 2017 | Member of Scientific Advisory Board |
Paul M. Karpecki | 56 | 2017 | Member of Scientific Advisory Board |
Victor Perez | - | 2018 | Member of Scientific Advisory Board |
Aron Shapiro | 45 | 2021 | Director |
Brian M. Strem | 43 | 2021 | President, CEO & Director |
Praveen Tyle | 63 | 2008 | Independent Chairman of the Board |
Kenneth L. Gayron | 53 | 2021 | Independent Director |
David A. Hollander | 49 | 2021 | Independent Director |
Erin Parsons | 47 | 2022 | Non-Employee Independent Director |
Charlie Wykoff | - | - | Member of Scientific Advisory Board |
Francis Mah | - | - | Member of Scientific Advisory Board |
Allen C. Ho | - | - | Member of Scientific Advisory Board |
Christine Kay | - | - | Member of Scientific Advisory Board |
Carmine N. Stengone | 47 | 2023 | Independent Director |
Russell Van Gelder | - | - | Member of Scientific Advisory Board |
Mark Pennesi | - | 2023 | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核